Poster Discussion Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Available Starting on Friday, June 4, 2021; 9:00 EDT
8511 Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. DR Spigel, C Faivre-Finn, IE Gray, et al
- In this 5-year updated analysis of the PACIFIC trial in patients with unresectable stage III NSCLC who have not progressed on platinum-based concurrent chemotherapy, the survival benefits of adding durvalumab to concurrent chemotherapy were durable and maintained. The overall survival was 47 months with durvalumab (n=473) versus 29 months with placebo (n=236), and the progression-free survival was 17 months versus 5.6 months.
- With a 43% overall survival rate for durvalumab at 60 months (vs 33% with placebo), these results highlight the continued benefit of durvalumab and extend the earlier results of the PACIFIC trial
Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic
Friday, June 4, 2021; 1:00 PM–4:00 PM EDT
9001 Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis. O Akinboro, JJ Vallejo, PS Mishra-Kalyani et al
- The authors conducted a pooled analysis of eeight randomized controlled trials to evaluate the use of anti–PD-(L)1 therapy in patients with advanced NSCLC and PD-L1 scores of 1%–49% (2108 patients identified). Those who received immunotherapy plus chemotherapy (n = 639) had median PFS and OS of 7.7 months and 21.4 months, respectively; those who received immunotherapy alone (n = 529) had median PFS and OS of 4.2 months and 14.5 months, respectively (median follow-up, 12.1 months).
- Immunotherapy plus chemotherapy may result in better patient outcomes than immunotherapy alone in this patient population.
9003 Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer. F Skoulidis, BT Li, R Govindan, et al
- In the phase II CodeBreaK 100 trial, sotorasib 960 mg was given orally once per day to patients with pretreated KRASG12C–mutated NSCLC. Next-generation sequencing of tissue samples was used to analyze mutant allele frequency and tumor mutational burden and to determine the mutational status of individual genes. The primary endpoint was ORR.
- Sotorasib was found to be clinically beneficial across all patient subgroups, and response was independent of KRASG12C–mutant allele frequency (OR, 1.11; 95% CI, 0.88–1.39).
9006 Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J Bauml, BC Cho, K Park, et al
- The authors present data from the CHRYSALIS study concerning the combination of 1050/1400 mg amivantamab and 240 mg lazertinib in 45 patients with osimertinib-relapsed, chemotherapy-naïve, EGFR-mutant NSCLC.
- In total, 16 patients demonstrated a confirmed response (1 complete, 15 partial), with 11 of the 16 remaining in response (2.6–9.6 months). Among the patients who responded, immunohistochemistry testing for EGFR and MET expression identified a subgroup more likely to respond to the drug combination. Of the 45 patients, 20 were still on treatment at a median follow-up of 8.2 months. Median PFS was 4.9 months.
9007 Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). PA Janne, CS Baik, W-C Su, et al
- The authors present data on the extended follow-up of 57 patients with locally advanced or metastatic EGFRm NSCLC and previous EGFR TKI therapy who received the recommended expansion dose of HER3-DXd, an antibody–drug conjugate (5.6 mg/kg IV every 3 weeks). The median duration of treatment was 5.5 months, and treatment was ongoing in 32% of patients. ORR was 39% (95% CI, 26.0%–52.4%); median duration of response was 6.9 months (95% CI, 3.1 months–not evaluable); median PFS was 8.2 months (95% CI, 4.4–8.3 months).
- HER3-DXd at a dose of 5.6 mg/kg IV every 3 weeks showed efficacy in patients heavily pretreated for locally advanced or metastatic EGFRm NSCLC. No new safety signals were identified.
9008 Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. JC-H Yang, M Wang, P Mitchell, et al
- Two phase I/II studies are ongoing to investigate the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of DZD9008, a rationally designed selective and irreversible EGFR exon20 insertion inhibitor. A total of 97 patients with NSCLC and EGFR or HER2 mutations received DZD9008 once daily (dose range, 50–400 mg).
- At doses ≥100 mg, partial response was seen, and the objective response rate was 48.4% (15/31) and the disease control rate 90.3% (28/31) at the recommended phase II dose of 300 mg. DZD9008 was well-tolerated up to the 400-mg dose, with the most common treatment-emergent adverse events being diarrhea (5.2%) and rash (1%).
Oral Abstract Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Sunday, June 6, 2021; 8:00 AM–11:00 AM EDT
8500 IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). HA Wakelee, NK Altorki, C Zhou, et al
- The authors present the primary disease-free survival results from the interim analysis of Impower010, a randomized phase III study of adjuvant atezolizumab. A total of 1269 patients with completely resected stage IB–IIIA NSCLC and ECOG performance status 0–1 received 4 cycles of cisplatin-based chemotherapy, with 1005 of these patients randomized to also receive either 16 cycles of atezolizumab or best supportive care.
- A statistically significant benefit in disease-free survival was observed for atezolizumab over best supportive care in patients with resected stage II–IIIA NSCLC, with notable benefit seen in the PD-L1 TC ≥1% subgroup. The safety profile was as expected from previous use of atezolizumab.
8503 Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). J Spicer, C Wang, F Tanaka, et al
- The CheckMate 816 study, a randomized phase III trial comparing neoadjuvant nivolumab + chemotherapy with chemotherapy alone for resectable NSCLC, demonstrated previously that the nivolumab + chemotherapy combination (nivo arm) significantly improved pathologic complete response. Here, the authors present the key surgical outcomes.
- In the nivo arm (n = 149), the definitive surgery rate was 83%; in the chemo arm (n = 135), it was 75%. Surgery was delayed due to adverse events for 6 patients in the nivo arm and 9 in the chemo arm, and surgery was cancelled due to disease progression for 12 patients in the nivo arm and 17 in the chemo arm. Rates of minimally invasive surgery were 30% and 22% for the nivo and chemo arms, respectively, with an 11% rate of conversion to open surgery for the nivo arm and 16% for the chemo arm. Rates of R0 resection and median residual viable tumor cells in the primary tumor bed were 83% and 10%, respectively, for the patients in the nivo arm and 78% and 74%, respectively, for patients in the chemo arm.